These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3296735)

  • 1. Methylprednisolone for the control of CMF-induced emesis.
    Chiara S; Campora E; Lionetto R; Bruzzi P; Rosso R
    Am J Clin Oncol; 1987 Jun; 10(3):264-7. PubMed ID: 3296735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: a randomized trial.
    Campora E; Chiara S; Bruzzi P; Scarsi P; Rosso R
    Tumori; 1985 Oct; 71(5):459-62. PubMed ID: 3904102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
    Gez E; Strauss N; Vitzhaki N; Cass Y; Edelmann DZ
    Cancer Chemother Pharmacol; 1992; 30(3):229-32. PubMed ID: 1628373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
    Gez E; Sulkes A; Ochayon L; Gera C; Nathan S; Cass Y; Rubello E; Biran S
    J Chemother; 1989 Dec; 1(6):365-8. PubMed ID: 2693621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.
    Campora E; Baldini E; Rubagotti A; Chiara S; Bruzzi P; Sertoli MR; Rosso R
    J Chemother; 1990 Oct; 2(5):336-9. PubMed ID: 2090773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo.
    Pollera CF; Nardi M; Marolla P; Pinnaró P; Terzoli E; Giannarelli D
    Am J Clin Oncol; 1989 Dec; 12(6):524-9. PubMed ID: 2589233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
    Roila F; Basurto C; Minotti V; Ballatori E; Tonato M; Del Favero A
    Oncology; 1988; 45(5):346-9. PubMed ID: 3412741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.
    Campora E; Oliva C; Mammoliti S; Cetto GL; Fosser V; Marangolo M; Rosso R
    Breast Cancer Res Treat; 1991 Oct; 19(2):129-32. PubMed ID: 1836746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
    Roila F; Tonato M; Basurto C; Minotti V; Ballatori E; del Favero A
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):615-7. PubMed ID: 3308477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
    Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
    Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy induced nausea and vomiting.
    Chiara S; Scarsi P; Campora E; Bruzzi P; Tatarek R; Rosso R
    Chemioterapia; 1984 Oct; 3(5):333-6. PubMed ID: 6398127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
    Domaradzka-Woźniak A; Wojtacki J; Dziewulska-Bokiniec A
    Przegl Lek; 1994; 51(5):203-5. PubMed ID: 7938648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
    Massidda B; Ionta MT
    J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
    Gez E; Warner-Efraty E; Ben-Yosef R; Ben-Baruch N; Yitzhaki N; Uziely B; Brufman G; Biran S
    Oncology; 1987; 44(4):237-9. PubMed ID: 3614813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
    Barrenetxea G; Schneider J; Centeno MM; Romero H; de la Rica M; Rodríguez-Escudero FJ
    Cancer Chemother Pharmacol; 1996; 38(5):471-5. PubMed ID: 8765442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
    J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
    J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
    Bonneterre J; Kerbrat P; Fargeot P; Metz R; Roche H; Bastit P; Chevrier A; Tubiana-Hulin M; Geyer G; Cappelaere P
    Eur J Cancer; 1991; 27(7):849-52. PubMed ID: 1834115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.